FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024956921> ?p ?o ?g. }

• W2024956921 endingPage "737" @default.
• W2024956921 startingPage "729" @default.
• W2024956921 abstract "Aims Most men with low-risk localised prostate cancer prefer treatments with high control rates and minimal disruption to their lives. Hypofractionating external radiation treatments can theoretically maintain high bioequivalent tumour doses, decrease treatment visits and decrease acute and late toxicities. The aim of this study was to assess the toxicity and feasibility of a hypofractionated accelerated regimen for these patients. Materials and methods The present study was a phase I/II study in which patients with T1–2b, Gleason ≤6 and prostate-specific antigen (PSA) ≤10 ng/ml prostate cancer received 35 Gy in five fractions, once a week over 29 days. Treatment was delivered with intensity-modulated radiotherapy on standard linear accelerators, with daily image guidance using gold seed fiducials, and a 4mm clinical target volume to planning target volume margin. Results As of January 2008, the target accrual of 30 patients had been reached and all had completed treatment and at least 6 months of follow-up. Dose–volume histogram objectives were achievable in all patients. Treatment was very well tolerated with no grade 3 or 4 genitourinary toxicity, gastrointestinal toxicity nor fatigue observed (95% confidence interval 0–12%). As a group, compared with baseline, the following additional grade 2 toxicities were observed: 13% genitourinary, 7% gastrointestinal and 10% fatigue. At 6 months all scores had returned to or improved over baseline. The median PSA before treatment was 6.0 ng/ml. At 6 months, the median PSA was 1.8 ng/ml and 75% had a PSA ≤3.0 ng/ml. Conclusions This novel technique using standard linear accelerators seems feasible and is well tolerated. Further follow-up will be carried out to document late toxicity and efficacy." @default.
• W2024956921 created "2016-06-24" @default.
• W2024956921 creator A5003931641 @default.
• W2024956921 creator A5015992547 @default.
• W2024956921 creator A5024524521 @default.
• W2024956921 creator A5025129662 @default.
• W2024956921 creator A5050240026 @default.
• W2024956921 creator A5050928951 @default.
• W2024956921 creator A5052285246 @default.
• W2024956921 creator A5056638686 @default.
• W2024956921 creator A5065835356 @default.
• W2024956921 creator A5070451444 @default.
• W2024956921 creator A5080491966 @default.
• W2024956921 date "2008-12-01" @default.
• W2024956921 modified "2023-10-10" @default.
• W2024956921 title "Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3" @default.
• W2024956921 cites W1968626722 @default.
• W2024956921 cites W1973462147 @default.
• W2024956921 cites W1978906140 @default.
• W2024956921 cites W1979914233 @default.
• W2024956921 cites W1981557414 @default.
• W2024956921 cites W1981868313 @default.
• W2024956921 cites W1987467806 @default.
• W2024956921 cites W1996809772 @default.
• W2024956921 cites W2002612178 @default.
• W2024956921 cites W2003218091 @default.
• W2024956921 cites W2006871146 @default.
• W2024956921 cites W2013184309 @default.
• W2024956921 cites W2016871222 @default.
• W2024956921 cites W2017298571 @default.
• W2024956921 cites W2019033634 @default.
• W2024956921 cites W2020538090 @default.
• W2024956921 cites W2029409133 @default.
• W2024956921 cites W2031657014 @default.
• W2024956921 cites W2035509954 @default.
• W2024956921 cites W2039139527 @default.
• W2024956921 cites W2043945205 @default.
• W2024956921 cites W2053948486 @default.
• W2024956921 cites W2056643793 @default.
• W2024956921 cites W2068882162 @default.
• W2024956921 cites W2076280910 @default.
• W2024956921 cites W2079491491 @default.
• W2024956921 cites W2096568394 @default.
• W2024956921 cites W2097532477 @default.
• W2024956921 cites W2104631398 @default.
• W2024956921 cites W2115675646 @default.
• W2024956921 cites W2117728681 @default.
• W2024956921 cites W2117792530 @default.
• W2024956921 cites W2130514725 @default.
• W2024956921 cites W2130574795 @default.
• W2024956921 cites W2137282952 @default.
• W2024956921 cites W2140023635 @default.
• W2024956921 cites W2148117492 @default.
• W2024956921 cites W2150373135 @default.
• W2024956921 cites W2152182740 @default.
• W2024956921 cites W2159598747 @default.
• W2024956921 cites W2163067324 @default.
• W2024956921 cites W2993539218 @default.
• W2024956921 cites W4244252755 @default.
• W2024956921 doi "https://doi.org/10.1016/j.clon.2008.08.006" @default.
• W2024956921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18838256" @default.
• W2024956921 hasPublicationYear "2008" @default.
• W2024956921 type Work @default.
• W2024956921 sameAs 2024956921 @default.
• W2024956921 citedByCount "72" @default.
• W2024956921 countsByYear W20249569212012 @default.
• W2024956921 countsByYear W20249569212013 @default.
• W2024956921 countsByYear W20249569212014 @default.
• W2024956921 countsByYear W20249569212015 @default.
• W2024956921 countsByYear W20249569212016 @default.
• W2024956921 countsByYear W20249569212017 @default.
• W2024956921 countsByYear W20249569212018 @default.
• W2024956921 countsByYear W20249569212019 @default.
• W2024956921 countsByYear W20249569212020 @default.
• W2024956921 countsByYear W20249569212021 @default.
• W2024956921 countsByYear W20249569212023 @default.
• W2024956921 crossrefType "journal-article" @default.
• W2024956921 hasAuthorship W2024956921A5003931641 @default.
• W2024956921 hasAuthorship W2024956921A5015992547 @default.
• W2024956921 hasAuthorship W2024956921A5024524521 @default.
• W2024956921 hasAuthorship W2024956921A5025129662 @default.
• W2024956921 hasAuthorship W2024956921A5050240026 @default.
• W2024956921 hasAuthorship W2024956921A5050928951 @default.
• W2024956921 hasAuthorship W2024956921A5052285246 @default.
• W2024956921 hasAuthorship W2024956921A5056638686 @default.
• W2024956921 hasAuthorship W2024956921A5065835356 @default.
• W2024956921 hasAuthorship W2024956921A5070451444 @default.
• W2024956921 hasAuthorship W2024956921A5080491966 @default.
• W2024956921 hasConcept C121608353 @default.
• W2024956921 hasConcept C126322002 @default.
• W2024956921 hasConcept C126894567 @default.
• W2024956921 hasConcept C133507102 @default.
• W2024956921 hasConcept C141071460 @default.
• W2024956921 hasConcept C143998085 @default.
• W2024956921 hasConcept C2776235491 @default.
• W2024956921 hasConcept C2777416452 @default.
• W2024956921 hasConcept C2780192828 @default.
• W2024956921 hasConcept C2781406297 @default.

• next